Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 2

Status

Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Gynecologic 1

Conditions

Peritoneal Neoplasms 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × LY-2157299 × Clear all
NCT05700656 2024-07-22

Galunisertib Combined With Capecitabine in Advanced CRC With PM

The Netherlands Cancer Institute

Phase 1/2 Recruiting
31 enrolled
GastrointestinalGynecologic

Peritoneal Neoplasms, Colorectal Neoplasms

NCT03470350 2019-07-24

EORTC1615

The Netherlands Cancer Institute

Phase 1/2 Withdrawn
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡